MDNA - Medicenna posts positive data from mid-stage brain cancer study

Medicenna Therapeutics ([[MDNA]] +2.3%) posted positive data from its Phase 2b trial testing its MDNA55 treatment in patients with recurrent glioblastoma ((rGBM)), the most common and uniformly fatal form of brain cancer.The results from the study were published in a peer-reviewed publication Clinical Cancer Research.The company said that it is "highly encouraged" by the results showing that early determination of progression free survival ((PFS)) using modified RANO ((mRANO)) may be a strong surrogate for overall survival in rGBM."We believe this finding and the positive mRANO PFS and overall survival ((OS)) data from our proposed patient population bode well for the outcome of the planned Phase 3 trial," CEO Fahar Merchant said.Medicenna is pursuing a partnership strategy to continue the Phase 3 development, Merchant added.

For further details see:

Medicenna posts positive data from mid-stage brain cancer study